{"id":"januvia-sitagliptin","safety":{"commonSideEffects":[{"rate":"7","effect":"Nasopharyngitis"},{"rate":"5","effect":"Headache"},{"rate":null,"effect":"Hypoglycemia (when combined with other agents)"},{"rate":"6","effect":"Upper respiratory tract infection"}]},"_chembl":{"chemblId":"CHEMBL1201174","moleculeType":"Small molecule","molecularWeight":"523.33"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking DPP-4 enzyme activity, sitagliptin prevents the degradation of GLP-1 and GIP, two incretin hormones that enhance glucose-dependent insulin secretion and suppress glucagon release. This mechanism leads to improved glycemic control in type 2 diabetes patients, particularly in the postprandial period, without causing hypoglycemia when used as monotherapy.","oneSentence":"Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), which increases levels of incretin hormones that stimulate insulin secretion in response to glucose.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:50:37.475Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02363335","phase":"PHASE1","title":"The Role of Phosphodiesterase Inhibitors in Incretin Secretion","status":"COMPLETED","sponsor":"National Institute on Aging (NIA)","startDate":"2015-02-13","conditions":"Healthy Volunteers","enrollment":29},{"nctId":"NCT07390110","phase":"","title":"Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-01-24","conditions":"Type 2 Diabetes, Heart Failure","enrollment":25664},{"nctId":"NCT06246799","phase":"PHASE3","title":"Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2024-11-07","conditions":"Type 2 Diabetes (Adult Onset)","enrollment":256},{"nctId":"NCT07452913","phase":"PHASE4","title":"Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes","status":"ENROLLING_BY_INVITATION","sponsor":"Bahria University","startDate":"2026-01-01","conditions":"Type 2 Diabetes Mellitus","enrollment":110},{"nctId":"NCT05042505","phase":"NA","title":"Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation","status":"COMPLETED","sponsor":"Medanta, The Medicity, India","startDate":"2022-01-01","conditions":"Diabetes Mellitus, Liver Transplant; Complications","enrollment":100},{"nctId":"NCT07439536","phase":"PHASE4","title":"Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2024-07-01","conditions":"Liver Cirrhosis With Diabetes","enrollment":64},{"nctId":"NCT07436663","phase":"PHASE4","title":"Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":150},{"nctId":"NCT06851962","phase":"PHASE4","title":"Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2025-05-26","conditions":"Diabetes Mellitus Type 2","enrollment":504},{"nctId":"NCT07417618","phase":"","title":"INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-01-27","conditions":"Type 2 Diabetes, Overweight, ASCVD","enrollment":60000},{"nctId":"NCT06813014","phase":"PHASE4","title":"Pharmacogenetics of Response to Sitagliptin (PRS)","status":"NOT_YET_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2026-12","conditions":"Diabetes","enrollment":400},{"nctId":"NCT07417631","phase":"","title":"Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-02-03","conditions":"Type 2 Diabetes","enrollment":30000},{"nctId":"NCT05149365","phase":"PHASE3","title":"Sitagliptin for Prevention of aGVHD After Alternative Donor Transplation","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-12-22","conditions":"Acute-graft-versus-host Disease, Allogeneic Hematopoietic Stem Cell Transplantation","enrollment":190},{"nctId":"NCT01794143","phase":"PHASE3","title":"A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"GRADE Study Group","startDate":"2013-05","conditions":"Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications","enrollment":7850},{"nctId":"NCT06914102","phase":"","title":"Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2025-01-14","conditions":"Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction","enrollment":58387},{"nctId":"NCT06914154","phase":"","title":"Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2025-01-14","conditions":"Diabetes Mellitus, Type 2, Heart Failure With Preserved Ejection Fraction (HFPEF)","enrollment":11265},{"nctId":"NCT07374328","phase":"PHASE1, PHASE2","title":"Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2025-06-01","conditions":"Type 2 Diabetes","enrollment":240},{"nctId":"NCT06263673","phase":"PHASE4","title":"Anti-Diabetic Medications to Fight PD and LBD","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2024-05-07","conditions":"Lewy Body Dementia, Parkinson Disease","enrollment":18},{"nctId":"NCT07365358","phase":"PHASE4","title":"Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients","status":"NOT_YET_RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2026-03","conditions":"Diabete Type 2","enrollment":200},{"nctId":"NCT07365592","phase":"PHASE1, PHASE2","title":"Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01-01","conditions":"Colorectal Cancer","enrollment":138},{"nctId":"NCT04323189","phase":"PHASE4","title":"Effects of Sitagliptin in Individuals With Genetically Decreased DPP4","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2020-08-26","conditions":"Genetics Disease, Type2 Diabetes, Heart Failure","enrollment":20},{"nctId":"NCT06560333","phase":"PHASE3","title":"iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD)","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-11-30","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT05367063","phase":"PHASE4","title":"Canagliflozin and Myocardial Fibrosis","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-01-05","conditions":"Type 2 Diabetes, Cardiovascular Risk","enrollment":45},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT06759922","phase":"PHASE4","title":"Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes","status":"COMPLETED","sponsor":"Bahria University","startDate":"2025-01-01","conditions":"Type 2 Diabetes Mellitus","enrollment":172},{"nctId":"NCT05768945","phase":"","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2022-11-30","conditions":"Diabetes","enrollment":742670},{"nctId":"NCT07203677","phase":"","title":"Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT)","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2025-09-19","conditions":"Type2 Diabetes Mellitus, Atherosclerotic Cardiovascular Disease","enrollment":49065},{"nctId":"NCT06659744","phase":"","title":"Emulation of the SUSTAIN6 Diabetes Trial Using Healthcare Claims","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2024-10-24","conditions":"Diabetes Mellitus, Type 2","enrollment":158310},{"nctId":"NCT07096063","phase":"","title":"Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2024-10-01","conditions":"Type 2 Diabetes, Overweight, Cardiovascular (CV) Risk","enrollment":887132},{"nctId":"NCT01471808","phase":"PHASE4","title":"Effects of Different Early Intensive Therapies on Long-term β-cell Function","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2011-10","conditions":"Diabetes Mellitus, Type 2","enrollment":264},{"nctId":"NCT07188545","phase":"","title":"Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2025-09-15","conditions":"Cardiovascular Kidney Metabolic Syndrome","enrollment":23280000},{"nctId":"NCT07172269","phase":"NA","title":"Mangosteen Supplement as Adjuvant Therapy With Sitagliptin/Metformin in Iraqi Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Mais Qais Hbeeb","startDate":"2024-09-15","conditions":"Diabete Mellitus, Type 2 Diabetes, Obesity Type 2 Diabetes Mellitus","enrollment":58},{"nctId":"NCT06972732","phase":"PHASE4","title":"A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2025-06-11","conditions":"Type 2 Diabetes","enrollment":204},{"nctId":"NCT02650427","phase":"PHASE1","title":"A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver Resection","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2016-02","conditions":"Hepato Carcinoma","enrollment":14},{"nctId":"NCT07083232","phase":"PHASE4","title":"The Effect of Sitagliptin, Pioglitazone and Dapagliflozine on Myocardial Infarction in Diabetic Rats","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2024-10-30","conditions":"Diabetic, Myocardial Infarction","enrollment":50},{"nctId":"NCT07003542","phase":"PHASE2","title":"A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2025-08-08","conditions":"Glioblastoma, Brain Tumor","enrollment":48},{"nctId":"NCT07108985","phase":"PHASE4","title":"Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2025-09","conditions":"Diabetes Mellitus, Type 2, Hyperglycemia, Insulin Resistance","enrollment":100},{"nctId":"NCT03738878","phase":"PHASE4","title":"Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2018-11-15","conditions":"Hypertension","enrollment":4},{"nctId":"NCT07076056","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2","status":"COMPLETED","sponsor":"Daewon Pharmaceutical Co., Ltd.","startDate":"2022-10-27","conditions":"Type 2 Diabetes","enrollment":230},{"nctId":"NCT02879409","phase":"NA","title":"HbA1c Variability in Type II Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Cornell Medical College in Qatar","startDate":"2016-11","conditions":"Diabetes Mellitus Type 2","enrollment":150},{"nctId":"NCT07073768","phase":"PHASE3","title":"Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients","status":"ENROLLING_BY_INVITATION","sponsor":"Khyber Medical College, Peshawar","startDate":"2025-07-01","conditions":"Diabetes Mellitus Type 2, Glycemic Control for Diabetes Mellitus","enrollment":126},{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":714582},{"nctId":"NCT06187285","phase":"NA","title":"Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of Hyperglycemia","status":"COMPLETED","sponsor":"Medanta, The Medicity, India","startDate":"2024-01-01","conditions":"Type 2 Diabetes","enrollment":220},{"nctId":"NCT01242228","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-10-21","conditions":"Type 2 Diabetes Mellitus","enrollment":106},{"nctId":"NCT06659679","phase":"","title":"Emulating the PIONEER6 Diabetes Trial Using Healthcare Claims","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2024-10-24","conditions":"Diabetes Mellitus, Type 2","enrollment":26126},{"nctId":"NCT06659718","phase":"","title":"Emulation of the SOUL Diabetes Trial in Healthcare Claims","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2024-10-24","conditions":"Diabetes Mellitus, Type 2","enrollment":43650},{"nctId":"NCT06952231","phase":"PHASE3","title":"Effect of Sitagliptin and Empagliflozin in Combination With Metformin on Hs-CRP Levels in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Lahore","startDate":"2024-05-21","conditions":"Diabetes Mellitus","enrollment":50},{"nctId":"NCT06329882","phase":"PHASE1, PHASE2","title":"Doxycycline in Type II Diabetes","status":"RECRUITING","sponsor":"Mostafa Bahaa","startDate":"2024-03-30","conditions":"Diabetes Mellitus, Type 2","enrollment":60},{"nctId":"NCT05556291","phase":"","title":"Combination of Ertugliflozin And Sitagliptin Efficacy, Safety & Tolerability (CEASE Diabetes) Study","status":"COMPLETED","sponsor":"Getz Pharma","startDate":"2022-12-01","conditions":"Efficacy, Safety, Tolerability","enrollment":190},{"nctId":"NCT04271189","phase":"PHASE3","title":"Managing DIabetes Remission After Combined Therapy in EarLy Stage of DiabetEs","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria di Parma","startDate":"2020-09-01","conditions":"Newly Diagnosed Type 2 Diabetes","enrollment":108},{"nctId":"NCT06875193","phase":"PHASE4","title":"DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes","status":"RECRUITING","sponsor":"Dong Wha Pharmaceutical Co. Ltd.","startDate":"2024-05-28","conditions":"Type2diabetes","enrollment":196},{"nctId":"NCT04409795","phase":"PHASE2, PHASE3","title":"Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study","status":"COMPLETED","sponsor":"Joslin Diabetes Center","startDate":"2021-08-26","conditions":"Type 1 Diabetes, Monogenic Diabetes","enrollment":3},{"nctId":"NCT02512523","phase":"PHASE4","title":"Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study)","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2015-08-27","conditions":"Type 2 Diabetes Mellitus","enrollment":39},{"nctId":"NCT06770894","phase":"PHASE3","title":"DPP4-Inhibitors and Bone Metabolism in Diabetes","status":"COMPLETED","sponsor":"Azienda Policlinico Umberto I","startDate":"2019-09-24","conditions":"Osteoporosis, Bone Loss, Postmenopausal, Diabetes Mellitus Type 2","enrollment":132},{"nctId":"NCT05900531","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers","status":"COMPLETED","sponsor":"Kallyope Inc.","startDate":"2022-09-21","conditions":"Obesity","enrollment":60},{"nctId":"NCT06054815","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH","status":"COMPLETED","sponsor":"NeuroBo Pharmaceuticals Inc.","startDate":"2023-09-14","conditions":"NON-ALCOHOLIC STEATOHEPATITIS","enrollment":109},{"nctId":"NCT02452632","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin","status":"COMPLETED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2015-06-22","conditions":"Type 2 Diabetes Mellitus","enrollment":143},{"nctId":"NCT04017832","phase":"PHASE3","title":"A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-07-29","conditions":"Diabetes Mellitus, Type 2","enrollment":1441},{"nctId":"NCT06613750","phase":"PHASE4","title":"Comparative Study of Sitagliptin and Gliclazide With Metformin in Type 2 Diabetes Patients With Glucotoxicity","status":"COMPLETED","sponsor":"Zhibin Xu","startDate":"2024-06-01","conditions":"Type 2 Diabetes Mellitus, Glucotoxicity","enrollment":129},{"nctId":"NCT05833958","phase":"PHASE2","title":"Polypill Versus Metformin in New Onset Type 2 Diabetes","status":"WITHDRAWN","sponsor":"George Medicines PTY Limited","startDate":"2024-09","conditions":"Type 2 Diabetes","enrollment":""},{"nctId":"NCT04017221","phase":"","title":"Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients with Type 2 Diabetes","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-10-01","conditions":"Diabetes Mellitus, Type 2, Urosepsis, Diabetic Ketoacidosis","enrollment":1249636},{"nctId":"NCT06587698","phase":"NA","title":"Sitagliptin or BeiDouGen Capsule Improve the Pregnancy Outcome in Patients with PCOS","status":"RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2024-08-21","conditions":"Polycystic Ovarian Syndrome","enrollment":300},{"nctId":"NCT03939624","phase":"","title":"Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-10-01","conditions":"Type2 Diabetes, Myocardial Infarction, Ischemic Stroke","enrollment":419734},{"nctId":"NCT04295005","phase":"","title":"A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-11-16","conditions":"Diabetes Mellitus, Type 2","enrollment":24500},{"nctId":"NCT06570980","phase":"","title":"Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.","status":"RECRUITING","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-08-25","conditions":"Type 2 Diabetes Mellitus (T2DM), Cost-effectiveness, Sulfonylureas, DPP4 Inhibitors, Metformin","enrollment":200},{"nctId":"NCT06515652","phase":"NA","title":"To Compare the Effects of Herbal Medicines With Traditional Allopathic Medicines in Cases of Patients With Metabolic Syndrome","status":"RECRUITING","sponsor":"Hamdard University","startDate":"2023-09-01","conditions":"Metabolic Syndrome","enrollment":200},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT04304261","phase":"PHASE3","title":"Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)","status":"COMPLETED","sponsor":"Third Military Medical University","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 2, Cognitive Functions Confusion","enrollment":100},{"nctId":"NCT01285076","phase":"","title":"Evaluation of Low Blood Sugar Events in Participants With Diabetes (MK-0431-401)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-10","conditions":"Type 2 Diabetes Mellitus","enrollment":834},{"nctId":"NCT05895201","phase":"PHASE1, PHASE2","title":"High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD","status":"WITHDRAWN","sponsor":"Indiana University","startDate":"2023-11","conditions":"Bone Marrow Transplant Complications, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Adult","enrollment":""},{"nctId":"NCT03918148","phase":"","title":"Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2018-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":1150},{"nctId":"NCT06233201","phase":"PHASE1","title":"Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Relative to Originator","status":"UNKNOWN","sponsor":"Bio-innova Co., Ltd","startDate":"2024-06-04","conditions":"Healthy Subjects","enrollment":34},{"nctId":"NCT06233240","phase":"PHASE1","title":"Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Relative to Originator","status":"UNKNOWN","sponsor":"Bio-innova Co., Ltd","startDate":"2024-04-30","conditions":"Healthy Subjects","enrollment":34},{"nctId":"NCT06204107","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2023-11-21","conditions":"Type 2 Diabetes Mellitus","enrollment":28},{"nctId":"NCT03014479","phase":"PHASE4","title":"Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-02-18","conditions":"Type 2 Diabetes","enrollment":219},{"nctId":"NCT06147518","phase":"NA","title":"To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2023-12-20","conditions":"Compensated Cirrhosis, Decompensated Cirrhosis","enrollment":240},{"nctId":"NCT06148259","phase":"NA","title":"SGLT Inhibitors Versus DDP4 Inhibitors and Prostate in Patient With Diabetes","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2021-03-12","conditions":"Diabetes Mellitus, Prostatic Hyperplasia","enrollment":57},{"nctId":"NCT06124495","phase":"PHASE1","title":"Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.","status":"COMPLETED","sponsor":"Galenicum Health","startDate":"2023-01-13","conditions":"Bioequivalence, Diabetes Mellitus, Type 2","enrollment":58},{"nctId":"NCT06124547","phase":"PHASE1","title":"Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.","status":"COMPLETED","sponsor":"Galenicum Health","startDate":"2023-01-16","conditions":"Bioequivalence, Diabetes Mellitus, Type 2","enrollment":48},{"nctId":"NCT06124560","phase":"PHASE1","title":"Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.","status":"COMPLETED","sponsor":"Galenicum Health","startDate":"2022-10-28","conditions":"Bioequivalence, Diabetes Mellitus, Type 2","enrollment":58},{"nctId":"NCT06124573","phase":"PHASE1","title":"Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.","status":"COMPLETED","sponsor":"Galenicum Health","startDate":"2022-11-07","conditions":"Bioequivalence, Diabetes Mellitus, Type 2","enrollment":48},{"nctId":"NCT06115460","phase":"PHASE3","title":"The Impact of Sitagliptin as an Add on Therapy With Closed Loop Control in Adolescents With Diabetic Nephropathy","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-03-01","conditions":"Type 1 Diabetic Nephropathy","enrollment":46},{"nctId":"NCT05579119","phase":"PHASE4","title":"SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H)","status":"COMPLETED","sponsor":"Hospital de Especialidades, Centro Medico Nacional \"La Raza\", Instituto Mexicano del Seguro Social","startDate":"2022-07-06","conditions":"Type 2 Diabetes","enrollment":76},{"nctId":"NCT00936663","phase":"PHASE4","title":"Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2009-07-06","conditions":"Type 2 Diabetes, End Stage Renal Disease","enrollment":3},{"nctId":"NCT05725798","phase":"","title":"Perioperative Sitagliptin Medication for Reduction of the Inflammatory Response Associated With Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"University Hospital Muenster","startDate":"2022-02-01","conditions":"Systemic Inflammatory Response Syndrome","enrollment":20},{"nctId":"NCT05972928","phase":"PHASE2, PHASE3","title":"Effect of Sitagliptin on Polycystic Ovarian Syndrome Patients","status":"UNKNOWN","sponsor":"Beni-Suef University","startDate":"2023-07-30","conditions":"Polycystic Ovary Syndrome","enrollment":80},{"nctId":"NCT04882813","phase":"","title":"Replication of the DAPA-CKD (Chronic Kidney Disease) Trial in Healthcare Claims Data","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-12-13","conditions":"Chronic Kidney Disease","enrollment":87727},{"nctId":"NCT04495881","phase":"PHASE4","title":"Sitagliptin for the Treatment of Type 2 Diabetes","status":"UNKNOWN","sponsor":"Beijing Chao Yang Hospital","startDate":"2020-01-01","conditions":"Type 2 Diabetes","enrollment":50},{"nctId":"NCT03936062","phase":"","title":"Replication of the TECOS Diabetes Trial in Healthcare Claims","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2017-09-22","conditions":"Diabetes","enrollment":349476},{"nctId":"NCT05099198","phase":"","title":"Replication of the GRADE Diabetes Trial in Healthcare Claims Data","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2018-09-01","conditions":"Diabetes","enrollment":6403},{"nctId":"NCT05870462","phase":"PHASE4","title":"Semaglutide and Vascular Regeneration","status":"UNKNOWN","sponsor":"Canadian Medical and Surgical Knowledge Translation Research Group","startDate":"2023-04-29","conditions":"Atherosclerosis, Cardiovascular Diseases, Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT05947825","phase":"PHASE2","title":"Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-07-30","conditions":"PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":30},{"nctId":"NCT01951339","phase":"NA","title":"Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2013-10","conditions":"Type 2 Diabetes, Cardiovascular Disease","enrollment":36},{"nctId":"NCT05161429","phase":"","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":550000},{"nctId":"NCT05219409","phase":"PHASE2, PHASE3","title":"Effects of Sitagliptin in Relatives of T1D Patients","status":"NOT_YET_RECRUITING","sponsor":"University of Milan","startDate":"2023-07","conditions":"Type 1 Diabetes","enrollment":70},{"nctId":"NCT05822674","phase":"","title":"Variable Effects of Anti-diabetics on Stress Hyperglycemia Ratio","status":"COMPLETED","sponsor":"University of Diyala","startDate":"2022-01-01","conditions":"Type 2 Diabetes","enrollment":80},{"nctId":"NCT05798715","phase":"PHASE1","title":"Bioequivalence Study of of Metformin HCl From Gleptomet 50/1000 mg F.C.Tablets (EVA Pharma, Egypt) and Janumet 50/1000 mg F.C.Tablets (Merck Sharp & Dohme, The Netherlands)","status":"COMPLETED","sponsor":"Genuine Research Center, Egypt","startDate":"2022-11-29","conditions":"Healthy","enrollment":30},{"nctId":"NCT03790839","phase":"PHASE1","title":"Drug Interaction Study Between Dorzagliatin and Sitagliptin","status":"COMPLETED","sponsor":"Hua Medicine Limited","startDate":"2019-01-31","conditions":"Patients","enrollment":15},{"nctId":"NCT02244164","phase":"NA","title":"Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.","status":"TERMINATED","sponsor":"Erasme University Hospital","startDate":"2014-10","conditions":"Type 2 Diabetes, Incretinomimetics, Pancreas","enrollment":5},{"nctId":"NCT05667220","phase":"PHASE4","title":"Sitagliptin in Combination With Beidougen Capsule for Type 2 Diabetes","status":"UNKNOWN","sponsor":"Beijing Chao Yang Hospital","startDate":"2022-12-01","conditions":"Type 2 Diabetes","enrollment":20},{"nctId":"NCT01928199","phase":"PHASE4","title":"Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2013-09","conditions":"Posttransplant Diabetes Mellitus","enrollment":61}],"_emaApprovals":[],"_faersSignals":[{"count":78,"reaction":"PANCREATITIS"},{"count":33,"reaction":"BLADDER CANCER"},{"count":25,"reaction":"NAUSEA"},{"count":24,"reaction":"DIARRHOEA"},{"count":22,"reaction":"RENAL FAILURE"},{"count":21,"reaction":"BLOOD GLUCOSE INCREASED"},{"count":17,"reaction":"FATIGUE"},{"count":16,"reaction":"DYSPNOEA"},{"count":15,"reaction":"CONSTIPATION"},{"count":15,"reaction":"RENAL FAILURE ACUTE"}],"_approvalHistory":[],"publicationCount":3326,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Januvia"],"phase":"marketed","status":"active","brandName":"Januvia (sitagliptin)","genericName":"Januvia (sitagliptin)","companyName":"Zealand University Hospital","companyId":"zealand-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), which increases levels of incretin hormones that stimulate insulin secretion in response to glucose. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}